Theravance Biopharma, Inc.
TBPH
$14.55
$0.251.75%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 128.54% | -30.30% | -2.22% | 13.40% | -105.26% |
| Total Depreciation and Amortization | -7.82% | -11.00% | -0.47% | 1.75% | -7.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -89.69% | -39.82% | -39.43% | 118.42% | 102.63% |
| Change in Net Operating Assets | 10,786.30% | 1,147.06% | 344.06% | -94.41% | -94.97% |
| Cash from Operations | 2,891.56% | 293.63% | 57.27% | 92.35% | 94.83% |
| Capital Expenditure | 71.03% | 85.31% | 86.66% | 60.57% | 58.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -150.27% | -5.72% | 139.77% | -142.31% | -98.69% |
| Cash from Investing | -155.18% | -5.44% | 137.57% | -157.12% | -98.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -64.86% | 1.29% | -1.94% | -18.82% | -22.21% |
| Repurchase of Common Stock | 96.42% | 98.44% | 98.44% | 83.69% | 75.97% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 96.72% | 98.87% | 98.74% | 83.93% | 92.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 497.60% | 142.43% | 99.32% | 86.07% | -423.71% |